...
首页> 外文期刊>British Journal of Cancer >A human natural antibody to adenocarcinoma that inhibits tumour cell migration
【24h】

A human natural antibody to adenocarcinoma that inhibits tumour cell migration

机译:人类天然抗腺癌抗体,可抑制肿瘤细胞迁移

获取原文
   

获取外文期刊封面封底 >>

       

摘要

We characterized a natural human antibody to adenocarcinomas and investigated the biological role of this Ab/Ag complex in cancer expansion. Human monoclonal antibodies (HuMAbs) were generated with hybridoma fusion methods using regional nodal lymphocytes of colon carcinoma patients. Among 1036 HuMAbs, only one, termed SK1, an IgM, was adenocarcinoma specific in the immunohistochemical study. The antigen recognized by SK1 (Ag-SK1) was a glycoprotein with a molecular weight of 42-46 kDa. The expression of Ag-SK1 on carcinoma cells varied according to the cell growth periods but was independent of cell cycle state as elucidated by two-colour fluorescence-activated cell sorter (FACS) analysis. A dot-blot analysis showed that the concentration of Ag-SK1 per total protein differed considerably among eight colon carcinoma cells examined and that the difference was closely correlated with the invasion capacity of the cells as assessed by a microchemotaxis assay. Furthermore, up to 87% of cell migration was inhibited by SK1 in a dose-dependent manner. These data suggested that Ag-SK1 is metabolized and expressed on highly invasive carcinoma cells. In addition, it appears that, although rare, some patients do mount an anti-cancer antigen response in their draining lymph nodes. A HuMAb such as SK1 may be a good candidate for the treatment of cancer invasion and metastasis.
机译:我们表征了天然人类针对腺癌的抗体,并研究了这种Ab / Ag复合物在癌症扩展中的生物学作用。人单克隆抗体(HuMAb)是通过杂交瘤融合方法使用结肠癌患者的区域淋巴结淋巴细胞生成的。在1036支HuMAb中,只有一种称为IgM SK1,在免疫组织化学研究中是腺癌特异性的。 SK1识别的抗原(Ag-SK1)是一种糖蛋白,分子量为42-46 kDa。 Ag-SK1在癌细胞上的表达随细胞的生长周期而变化,但与细胞周期状态无关,如通过两色荧光激活细胞分选仪(FACS)分析所阐明的。点印迹分析显示,在所检查的八种结肠癌细胞中,每种蛋白质中Ag-SK1的浓度存在很大差异,并且该差异与通过微趋化分析评估的细胞侵袭能力密切相关。此外,SK1以剂量依赖的方式抑制了高达87%的细胞迁移。这些数据表明Ag-SK1在高侵袭性癌细胞上被代谢并表达。此外,似乎有些患者尽管引流淋巴结中确实有抗癌抗原反应,尽管这种情况很少见。 HuMAb(例如SK1)可能是治疗癌症侵袭和转移的好候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号